Cargando…

From Leflunomide to Teriflunomide: Drug Development and Immuno-suppressive Oral Drugs in the Treatment of Multiple Sclerosis

BACKGROUND: Immunosuppressive drugs have been used in the treatment of multiple sclerosis (MS) for a long time. Today, orally available second generation immunosuppressive agents have been approved or are filed for licensing as MS therapeutics. Due to semi-selective targeting of cellular processes,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aly, Lilian, Hemmer, Bernhard, Korn, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652031/ https://www.ncbi.nlm.nih.gov/pubmed/27928949 http://dx.doi.org/10.2174/1570159X14666161208151525

Ejemplares similares

Role of oral teriflunomide in the management of multiple sclerosis
por: Tanasescu, Radu, et al.
Publicado: (2013)

Painful Small Fiber Neuropathy Associated With Teriflunomide: A Case Series and Literature Review Related to Teriflunomide and Leflunomide
por: Elrefaey, Ahmed, et al.
Publicado: (2023)

Selective Binding of Cyclodextrins with Leflunomide and Its Pharmacologically Active Metabolite Teriflunomide
por: Terekhova, Irina, et al.
Publicado: (2020)

An update of teriflunomide for treatment of multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2013)

On the interactions of leflunomide and teriflunomide within receptor cavity — NMR studies and energy calculations
por: Kujawski, Jacek, et al.
Publicado: (2015)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2014)

Neuropathy in multiple sclerosis patients treated with teriflunomide
por: Kilic, Ahmet Kasim, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide: Should Consideration Be Given to Cannalicular Efflux Transporters?
por: Srinivas, NR
Publicado: (2015)

Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication
por: Bilger, Andrea, et al.
Publicado: (2017)

Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels
por: Fajardo-Robledo, Nicte S., et al.
Publicado: (2022)

Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors “leflunomide” and “teriflunomide” in Covid-19: A narrative review
por: Kaur, Hardeep, et al.
Publicado: (2021)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

COVID-19 in teriflunomide-treated patients with multiple sclerosis
por: Maghzi, Amir Hadi, et al.
Publicado: (2020)

Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2020)

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
por: Tornatore, Carlo, et al.
Publicado: (2022)

Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis
por: Thiele née Schrewe, Lisa, et al.
Publicado: (2020)

Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience
por: Miller, Aaron E.
Publicado: (2017)

Lichenoid Drug Eruption Induced by Teriflunomide
por: Agharbi, Fatima-Zahra, et al.
Publicado: (2023)

Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide—Should Consideration Be Given to Cannalicular Efflux Transporters?
por: Hopkins, AM, et al.
Publicado: (2015)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
por: Bayas, Antonios, et al.
Publicado: (2015)

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2020)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth
por: Hanson, Kimberley, et al.
Publicado: (2017)

Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis
por: Noll, Christina, et al.
Publicado: (2022)

Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells
por: Tilly, Gaëlle, et al.
Publicado: (2021)

Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status
por: Kallmann, Boris A., et al.
Publicado: (2021)

Teriflunomide treatment outcomes in multiple sclerosis: A Portuguese real-life experience
por: Nunes, Carla Cecília, et al.
Publicado: (2023)

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2013)

Safe Childbirth after Taking Teriflunomide in a Woman with Multiple Sclerosis
por: Cho, Bang-Hoon, et al.
Publicado: (2018)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

8. Myositis as an idiosyncratic drug reaction to leflunomide
por: Darren, Angeline, et al.
Publicado: (2019)

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
por: Cohan, Stanley L, et al.
Publicado: (2019)

Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth
por: Hanson, Kimberley, et al.
Publicado: (2018)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis
por: Fissolo, Nicolás, et al.
Publicado: (2022)

Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19
por: Rabie, Amgad M.
Publicado: (2021)

Teriflunomide – The common drug with underestimated oxygen - Dependent anticancer potential
por: Otto-Ślusarczyk, Dagmara, et al.
Publicado: (2021)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n1hsa9qm2fnucme5rf172qrtbf